Competing interests
N.H.
Z.D.C.: research funding, BioLineRx; M.P.R.: no competing interests. R.G.J.: consulting fees, WUGEN. K.S.-G.: research funding, BioLineRx, Caelum Biosciences, GlaxoSmithKline, GlycoMimetics, Ionis Pharmaceuticals, Janssen Pharmaceuticals, Millennium Pharmaceuticals (Takeda), Sanofi; equity stock/ownership, Abbott, AbbVie; consulting Fees, GlaxoSmithKline; board or advisory committee membership, GlaxoSmithKline; speaking fees, Janssen Pharmaceuticals; expert witness, Celgene. G.A.M., M.M., P.S.: no competing interests. I.A.: consulting fees and board or advisory committee membership, Janssen, Celgene, Novartis, Pfizer, Takeda, Roche. D.S: consulting fees, Janssen, AbbVie, Sanofi, GlaxoSmithKline, BristolMyersSquibb, Pfizer; board or advisory committee membership, Janssen, Sanofi, GlaxoSmithKline. D.P.: no competing interests. I.M.: research funding, BioLineRx. G.M.J.: no competing interests. G.M.: research funding, AbbVie, Janssen-Cilag; consulting fees, AbbVie, Amgen, Bristol-Myers-Squibb/Celgene, Janssen-Cilag, Krka, Novartis, Roche, Takeda. M.L.P.C.: no competing interests. U.H.: consulting fees, Sanofi-Adventis. J.H.: no competing interests. M.H.Q.: research funding, Janssen Pharmaceuticals, BioLineRx, Angiocrrine, Neximmune. N.H.: board or advisory committee membership, Incyte, Kite/Gilead, American Gene Technologies. T.L., I.G.-C.: no competing interests. A.V.-H., E.S., I.G.-K., I.G., D.I., L.S.-D.: employment, BioLineRx. S.K., F.G.: no competing interests. M.A.S.: research funding, Incyte, Cellect, Inc., Equillium, Inc., Fortis, Seattle Genetics, Amgen, Celgene, PBD, Inc., Sanofi Genzyme, Janssen; consulting fees and board or advisory committee membership, Advarra, Amgen, Astellas, CareDx, Dova pharmaceuticals, Equillium, Inc., FlatIron, Inc., GlaxoSmithKline, Gilead Sciences, Inc., Incyte, Inmagene Bio, Janssen, Novo Nordisk, Partners Therapeutics, Pfizer, Sanofi Genzyme, StemLine. R.V.: no competing interests. J.F.D.: equity stock/ownership, Magenta Therapeutics, WUGEN; consulting fees, Incyte, RiverVest Venture Partners; board or advisory committee membership, Cellworks Group, RiverVest Venture Partners, Magenta; research funding, Amphivena Therapeutics, NeoImmune Tech, Macrogenics, Incyte, BioLineRx, WUGEN; speaking fees, Incyte; patents (nos. PCT/US2019/035010 and PCT/US2019/035052), WUGEN, Magenta.